R

Rhythm Pharmaceuticals
D

RYTM

57.270
USD
-0.21
(-0.37%)
مغلق
حجم التداول
8,499
الربح لكل سهم
-3
العائد الربحي
-
P/E
-13
حجم السوق
3,519,646,342
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARWR
    -0.050
    (-0.25%)
    19.710 USD
    C
    CRBP
    -0.620
    (-5.18%)
    11.350 USD
    C
    CRSP
    2.740
    (6.61%)
    44.200 USD
    E
    EDIT
    0.15000
    (12.50%)
    1.35000 USD
    N
    NTLA
    1.040
    (10.45%)
    10.990 USD
    P
    PRQR
    0.00000
    (0.00%)
    2.23000 USD
    Q
    QURE
    0.390
    (2.61%)
    15.310 USD
    R
    RARE
    1.650
    (4.00%)
    42.950 USD
    S
    SGMO
    0.03500
    (3.13%)
    1.15500 USD
    V
    VYGR
    0.22000
    (4.21%)
    5.45000 USD
    المزيد
الأخبار
المقالات

العنوان: Rhythm Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.